dc.contributor
Institut Català de la Salut
dc.contributor
[Ruiz de Morales JMG] Inmunology Unit, Complejo Asistencial Universitario e Instituto de Biomedicina Universidad de León (IBIOMED), León, Spain. [Puig L] Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Daudén E] Dermatology Department, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Hospital Universitario de la Princesa, Madrid, Spain. [Cañete JD] Arthritis Unit, Rheumatology Dpt.,Hospital Clinic and IDIBAPS, Barcelona, Spain. [Pablos JL] Rheumatology Department, Hospital 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain. [Martín AO] Gastroenterology Department, La Paz Universitary Hospital, Madrid, Spain. [Montalbán X] Servei de Neurologia/Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Borruel N] Unitat d’Atenció Crohn-Colitis, Unitat de Recerca en Aparell Digestiu, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ortí G] Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Ruiz de Morales, José María G.
dc.contributor.author
Puig, Lluís
dc.contributor.author
Daudén, Esteban
dc.contributor.author
Cañete, Juan D.
dc.contributor.author
Pablos, José Luis
dc.contributor.author
Olveira Martín, Antonio
dc.contributor.author
Montalban Gairín, Xavier
dc.contributor.author
Borruel Sainz, Natalia
dc.contributor.author
Orti Pascual, Guillem
dc.date.accessioned
2023-11-08T10:22:41Z
dc.date.available
2023-11-08T10:22:41Z
dc.date.issued
2021-10-01T08:06:18Z
dc.date.issued
2021-10-01T08:06:18Z
dc.identifier
Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmun Rev. 2020 Jan;19:102429.
dc.identifier
https://hdl.handle.net/11351/6373
dc.identifier
10.1016/j.autrev.2019.102429
dc.identifier
000508749200008
dc.identifier.uri
http://hdl.handle.net/11351/6373
dc.description.abstract
Medicaments biològics; Inflamació; Psoriasi
dc.description.abstract
Biological drugs; Inflammation; Psoriasis
dc.description.abstract
Medicamentos biológicos; Inflamación; Psoriasis
dc.description.abstract
Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.
dc.description.abstract
This work was supported by Novartis Pharmaceuticals Spain.
dc.format
application/pdf
dc.relation
Autoimmunity Reviews;19
dc.relation
https://doi.org/10.1016/j.autrev.2019.102429
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Citocines - Immunologia
dc.subject
DISEASES::Skin and Connective Tissue Diseases::Skin Diseases::Skin Diseases, Papulosquamous::Psoriasis
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Intercellular Signaling Peptides and Proteins::Cytokines
dc.subject
Other subheadings::Other subheadings::Other subheadings::/immunology
dc.subject
ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::enfermedades cutáneas papuloescamosas::psoriasis
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::péptidos y proteínas de señalización intercelular::citocinas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/inmunología
dc.title
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
